Search
Now showing items 1-10 of 533
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
(2020-08)
Background The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma ...
Improving outcomes for the lung cancer patient with impaired lung function
(Institute of Cancer Research (University Of London), 2021-03-31)
Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ...
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
(2020-11)
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new ...
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
(2021-05-12)
Purpose Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using ...
Applications of liquid biopsies in metastatic castration resistant prostate cancer
(Institute of Cancer Research (University Of London), 2020-02-29)
Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ...
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ...
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
(2021-10-06)
<h4>Purpose</h4>The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association ...
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
(AMER MEDICAL ASSOC, 2022-05-02)
Importance: There is a need to tailor treatments to patients who are most likely to derive the greatest benefit from them to improve patient outcomes and enhance cost-effectiveness of cancer therapies. Objective: To compare ...
Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.
(Wiley, 2021-03-01)
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment ...